1. Clinical Overview
Pneumococcal Polysaccharide Vaccine (PPSV23) is a sterile, liquid vaccine containing purified capsular polysaccharide antigens from 23 serotypes of Streptococcus pneumoniae (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). Each 0.5 mL dose contains 25 mcg of each polysaccharide type (total 575 mcg) dissolved in isotonic saline solution containing 0.25% phenol as a preservative. The 16mcg reference often pertains to the antigenic content per serotype in some presentations or is a common misnomer; the standard is 25mcg per serotype. It induces type-specific antibody production, providing protection against invasive pneumococcal disease (IPD) like meningitis, bacteremia, and pneumonia caused by the included serotypes.
| Onset | Duration | Bioavailability |
|---|---|---|
| Protective antibody levels are typically achieved within 2-3 weeks post-vaccination. | Protection is long-lasting but not lifelong. Antibody levels decline after 5-10 years, and revaccination may be indicated for high-risk groups. | Not applicable (N/A) for parenteral vaccines. The vaccine is administered via intramuscular or subcutaneous injection, ensuring 100% systemic delivery of the antigenic stimulus. |
2. Mechanism of Action
The vaccine contains purified, high molecular weight capsular polysaccharides from the pneumococcal bacterial cell wall. When injected, these antigens are recognized by the immune system as foreign. They directly stimulate mature B-lymphocytes in the spleen and other lymphoid tissues, leading to the production of type-specific opsonizing IgG antibodies without the assistance of T-helper cells (T-cell independent response). These antibodies facilitate opsonization and phagocytosis of the bacteria by neutrophils and macrophages, preventing invasive disease.
3. Indications & Uses
- Active immunization for the prevention of invasive pneumococcal disease (IPD) caused by the 23 included serotypes in adults aged 50 years and older.
- Immunization of individuals aged 2 years and older who are at increased risk for pneumococcal disease due to chronic illnesses (e.g., cardiovascular disease, pulmonary disease, diabetes mellitus, alcoholism, chronic liver disease, CSF leaks).
- Immunization of immunocompromised individuals (e.g., HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure, nephrotic syndrome, organ transplant recipients) and those receiving immunosuppressive therapy.
4. Dosage & Administration
Adult Dosage: A single 0.5 mL dose administered intramuscularly (preferred) or subcutaneously.
Administration: Shake the vial or pre-filled syringe well before use to obtain a uniform, cloudy white suspension. Administer by IM injection into the deltoid muscle or anterolateral thigh. Do not inject intravenously, intradermally, or subcutaneously into the same site repeatedly. Use a separate, sterile syringe and needle for each patient.
5. Side Effects
Common side effects may include:
- Pain, tenderness, redness, and induration at the injection site (up to 60-70% of recipients).
- Mild fever (<38.3°C / 101°F).
- Malaise, myalgia, headache.
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Immunosuppressive Therapies (e.g., high-dose corticosteroids, chemotherapy, radiation, biologics like TNF inhibitors) | May diminish the immunological response to the vaccine, leading to suboptimal antibody production. | Major |
| Pneumococcal Conjugate Vaccine (PCV13, PCV15, PCV20) | Sequential administration is recommended for high-risk adults (PCV13/15 first, followed by PPSV23 at least 8 weeks later). Concomitant administration is not recommended as it may lead to a blunted antibody response to the PPSV23 serotypes. | Major |
| Influenza Vaccine (Inactivated) | Can be administered concomitantly at different injection sites. No significant interference in immunogenicity or increase in adverse events. | Minor |
| Zoster Vaccine (Recombinant) | Can be administered concomitantly. Studies show no significant interference. | Minor |
| Anticoagulants (Warfarin, DOACs) | Increased risk of bleeding or hematoma from intramuscular injection. Use a fine-gauge needle and apply firm pressure for ≥5 minutes. | Moderate |
7. Patient Counselling
- DO inform your doctor about any allergies, especially to vaccine components or previous vaccines.
- DO report if you are pregnant, planning pregnancy, or breastfeeding.
- DO expect common side effects like arm soreness, redness, or mild fever; these usually resolve in 1-2 days.
- DO apply a clean, cool, wet cloth over the injection site for comfort.
- DO use an antipyretic/analgesic (e.g., paracetamol) for fever or pain if needed, unless contraindicated.
- DONT take the vaccine if you have a high fever or severe acute illness on the day of vaccination.
- DONT rub or massage the injection site vigorously.
8. Toxicology & Storage
Overdose: Overdose is unlikely due to single-dose packaging. Theoretical risks include exacerbation of common side effects: severe local reaction with extensive swelling, pain, redness; high fever; pronounced systemic symptoms like malaise and headache.
Storage: Store at +2°C to +8°C (in a refrigerator). Do not freeze. Protect from light. Do not use if the vaccine has been frozen. The vaccine is a uniform, cloudy white suspension. Do not use if it appears clear or contains particulate matter. Use immediately after opening the vial. Keep out of reach of children.